ARTICLE | Company News
InterMune submits NDS for Actimmune
January 4, 2001 8:00 AM UTC
ITMN submitted an NDS in Canada for its Actimmune interferon gamma-1b to treat chronic granulomatous disease and severe malignant osteopetrosis. The NDS has priority review. Actimmune is marketed in t...